In addition, our previous report revealed a significantly higher incidence of occult lymph node metastases in ALK-positive NSCLC, which makes these patients good candidates for adjuvant chemotherapy according to the clinical guidelines [14]. This evidence concerns the gene ALK and non-small cell lung carcinoma.